196 related articles for article (PubMed ID: 38598070)
1. Photobiomodulation therapy moderates cancer cachexia-associated muscle wasting through activating PI3K/AKT/FoxO3a pathway.
Li Y; Chen Y; Liao Y; Huang T; Tang Q; He C; Xu L; Chang H; Li H; Liu Q; Lai D; Xia Q; Zou Z
Apoptosis; 2024 Jun; 29(5-6):663-680. PubMed ID: 38598070
[TBL] [Abstract][Full Text] [Related]
2. Matrine improves skeletal muscle atrophy by inhibiting E3 ubiquitin ligases and activating the Akt/mTOR/FoxO3α signaling pathway in C2C12 myotubes and mice.
Chen L; Chen L; Wan L; Huo Y; Huang J; Li J; Lu J; Xin B; Yang Q; Guo C
Oncol Rep; 2019 Aug; 42(2):479-494. PubMed ID: 31233199
[TBL] [Abstract][Full Text] [Related]
3. Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study.
Yuan L; Han J; Meng Q; Xi Q; Zhuang Q; Jiang Y; Han Y; Zhang B; Fang J; Wu G
Oncol Rep; 2015 May; 33(5):2261-8. PubMed ID: 25760630
[TBL] [Abstract][Full Text] [Related]
4. Cryptotanshinone prevents muscle wasting in CT26-induced cancer cachexia through inhibiting STAT3 signaling pathway.
Chen L; Yang Q; Zhang H; Wan L; Xin B; Cao Y; Zhang J; Guo C
J Ethnopharmacol; 2020 Oct; 260():113066. PubMed ID: 32505837
[TBL] [Abstract][Full Text] [Related]
5. SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth.
Lee D; Goldberg AL
J Biol Chem; 2013 Oct; 288(42):30515-30526. PubMed ID: 24003218
[TBL] [Abstract][Full Text] [Related]
6. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
7. Signaling pathways perturbing muscle mass.
Glass DJ
Curr Opin Clin Nutr Metab Care; 2010 May; 13(3):225-9. PubMed ID: 20397318
[TBL] [Abstract][Full Text] [Related]
8. Iron-induced skeletal muscle atrophy involves an Akt-forkhead box O3-E3 ubiquitin ligase-dependent pathway.
Ikeda Y; Imao M; Satoh A; Watanabe H; Hamano H; Horinouchi Y; Izawa-Ishizawa Y; Kihira Y; Miyamoto L; Ishizawa K; Tsuchiya K; Tamaki T
J Trace Elem Med Biol; 2016 May; 35():66-76. PubMed ID: 27049128
[TBL] [Abstract][Full Text] [Related]
9. Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation.
Quan-Jun Y; Yan H; Yong-Long H; Li-Li W; Jie L; Jin-Lu H; Jin L; Peng-Guo C; Run G; Cheng G
Mol Cancer Ther; 2017 Feb; 16(2):334-343. PubMed ID: 27599525
[TBL] [Abstract][Full Text] [Related]
10. Forkhead box O3 plays a role in skeletal muscle atrophy through expression of E3 ubiquitin ligases MuRF-1 and atrogin-1 in Cushing's syndrome.
Kang SH; Lee HA; Kim M; Lee E; Sohn UD; Kim I
Am J Physiol Endocrinol Metab; 2017 Jun; 312(6):E495-E507. PubMed ID: 28246104
[TBL] [Abstract][Full Text] [Related]
11. C/EBPβ mediates tumour-induced ubiquitin ligase atrogin1/MAFbx upregulation and muscle wasting.
Zhang G; Jin B; Li YP
EMBO J; 2011 Aug; 30(20):4323-35. PubMed ID: 21847090
[TBL] [Abstract][Full Text] [Related]
12. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors.
Stitt TN; Drujan D; Clarke BA; Panaro F; Timofeyva Y; Kline WO; Gonzalez M; Yancopoulos GD; Glass DJ
Mol Cell; 2004 May; 14(3):395-403. PubMed ID: 15125842
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy.
Reed SA; Sandesara PB; Senf SM; Judge AR
FASEB J; 2012 Mar; 26(3):987-1000. PubMed ID: 22102632
[TBL] [Abstract][Full Text] [Related]
14. Regulation of the intracellular localization of Foxo3a by stress-activated protein kinase signaling pathways in skeletal muscle cells.
Clavel S; Siffroi-Fernandez S; Coldefy AS; Boulukos K; Pisani DF; Dérijard B
Mol Cell Biol; 2010 Jan; 30(2):470-80. PubMed ID: 19917721
[TBL] [Abstract][Full Text] [Related]
15. Electrical stimulation prevents doxorubicin-induced atrophy and mitochondrial loss in cultured myotubes.
Guigni BA; Fix DK; Bivona JJ; Palmer BM; Carson JA; Toth MJ
Am J Physiol Cell Physiol; 2019 Dec; 317(6):C1213-C1228. PubMed ID: 31532714
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia.
Silva KA; Dong J; Dong Y; Dong Y; Schor N; Tweardy DJ; Zhang L; Mitch WE
J Biol Chem; 2015 Apr; 290(17):11177-87. PubMed ID: 25787076
[TBL] [Abstract][Full Text] [Related]
17. Cancer-Induced Muscle Wasting Requires p38β MAPK Activation of p300.
Sin TK; Zhang G; Zhang Z; Zhu JZ; Zuo Y; Frost JA; Li M; Li YP
Cancer Res; 2021 Feb; 81(4):885-897. PubMed ID: 33355181
[TBL] [Abstract][Full Text] [Related]
18. Epigallocatechin-3-gallate effectively attenuates skeletal muscle atrophy caused by cancer cachexia.
Wang H; Lai YJ; Chan YL; Li TL; Wu CJ
Cancer Lett; 2011 Jun; 305(1):40-9. PubMed ID: 21397390
[TBL] [Abstract][Full Text] [Related]
19. Small-Molecule Chemical Knockdown of MuRF1 in Melanoma Bearing Mice Attenuates Tumor Cachexia Associated Myopathy.
Adams V; Gußen V; Zozulya S; Cruz A; Moriscot A; Linke A; Labeit S
Cells; 2020 Oct; 9(10):. PubMed ID: 33050629
[No Abstract] [Full Text] [Related]
20. Formononetin ameliorates muscle atrophy by regulating myostatin-mediated PI3K/Akt/FoxO3a pathway and satellite cell function in chronic kidney disease.
Liu L; Hu R; You H; Li J; Liu Y; Li Q; Wu X; Huang J; Cai X; Wang M; Wei L
J Cell Mol Med; 2021 Feb; 25(3):1493-1506. PubMed ID: 33405354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
